Tags

Type your tag names separated by a space and hit enter

New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women.
Menopause 2009 Jan-Feb; 16(1):141-8M

Abstract

OBJECTIVES

Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a major role in the health benefits of soy. We examined the effect of a new S-equol supplement on menopausal symptoms and mood states.

DESIGN

We conducted a randomized, double-blind, placebo-controlled trial with our new equol supplement for 12 weeks with 134 Japanese women (aged 40-59 years). They were randomly assigned to three groups: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol three times per day (EQ-3; n = 46). Habitual isoflavone intake was limited to 20 mg/d. Participants completed menopausal symptom and Profile of Mood States questionnaires at baseline and postintervention. Physical examination and blood and 24-hour urine collection were performed at baseline and postintervention.

RESULTS

At baseline, total menopausal symptom score varied by menopausal and equol producer status (34.3% producers). A total of 127 participants (94.8%) completed the trial. No adverse effects were reported, except for a systemic rash in one EQ-3 woman. The anxiety scores of equol producers were lower than those of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States.

CONCLUSION

S-equol supplement improved mood-related symptoms in perimenopausal/postmenopausal equol nonproducers.

Authors+Show Affiliations

Department of Life Environments Management, Atomi University, Niza-shi, Saitama, Japan. ishiwata@atomi.ac.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19131846

Citation

Ishiwata, Naoko, et al. "New Equol Supplement for Relieving Menopausal Symptoms: Randomized, Placebo-controlled Trial of Japanese Women." Menopause (New York, N.Y.), vol. 16, no. 1, 2009, pp. 141-8.
Ishiwata N, Melby MK, Mizuno S, et al. New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause. 2009;16(1):141-8.
Ishiwata, N., Melby, M. K., Mizuno, S., & Watanabe, S. (2009). New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. Menopause (New York, N.Y.), 16(1), pp. 141-8. doi:10.1097/gme.0b013e31818379fa.
Ishiwata N, et al. New Equol Supplement for Relieving Menopausal Symptoms: Randomized, Placebo-controlled Trial of Japanese Women. Menopause. 2009;16(1):141-8. PubMed PMID: 19131846.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - New equol supplement for relieving menopausal symptoms: randomized, placebo-controlled trial of Japanese women. AU - Ishiwata,Naoko, AU - Melby,Melissa K, AU - Mizuno,Shoichi, AU - Watanabe,Shaw, PY - 2009/1/10/entrez PY - 2009/1/10/pubmed PY - 2009/4/10/medline SP - 141 EP - 8 JF - Menopause (New York, N.Y.) JO - Menopause VL - 16 IS - 1 N2 - OBJECTIVES: Equol, a metabolite of the isoflavone daidzein, is hypothesized to play a major role in the health benefits of soy. We examined the effect of a new S-equol supplement on menopausal symptoms and mood states. DESIGN: We conducted a randomized, double-blind, placebo-controlled trial with our new equol supplement for 12 weeks with 134 Japanese women (aged 40-59 years). They were randomly assigned to three groups: placebo (n = 44), 10 mg of equol per day (EQ-1; n = 44), and 10 mg of equol three times per day (EQ-3; n = 46). Habitual isoflavone intake was limited to 20 mg/d. Participants completed menopausal symptom and Profile of Mood States questionnaires at baseline and postintervention. Physical examination and blood and 24-hour urine collection were performed at baseline and postintervention. RESULTS: At baseline, total menopausal symptom score varied by menopausal and equol producer status (34.3% producers). A total of 127 participants (94.8%) completed the trial. No adverse effects were reported, except for a systemic rash in one EQ-3 woman. The anxiety scores of equol producers were lower than those of nonproducers (P < 0.05). Significant differences between premenopausal and perimenopausal/postmenopausal symptom scores were observed for anxiety, somatic, and total scores. After the EQ-3 intervention, perimenopausal/postmenopausal equol nonproducers showed significant decreases from baseline in all menopausal symptom scores except depression (P < 0.01). Compared with placebo, the EQ-3 group showed significant decreases in depression scores (P < 0.05), as well as significant decreases in Tension-Anxiety (P < 0.05), Depression-Dejection (P < 0.05) and Fatigue (P < 0.01) and increases in Vigor (P < 0.05) of the Profile of Mood States. CONCLUSION: S-equol supplement improved mood-related symptoms in perimenopausal/postmenopausal equol nonproducers. SN - 1530-0374 UR - https://www.unboundmedicine.com/medline/citation/19131846/New_equol_supplement_for_relieving_menopausal_symptoms:_randomized_placebo_controlled_trial_of_Japanese_women_ L2 - http://Insights.ovid.com/pubmed?pmid=19131846 DB - PRIME DP - Unbound Medicine ER -